Integer Holdings Co. (NYSE:ITGR) Short Interest Update

Integer Holdings Co. (NYSE:ITGR) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 2,660,000 shares, a growth of 19.8% from the February 28th total of 2,220,000 shares. Based on an average trading volume of 370,400 shares, the days-to-cover ratio is presently 7.2 days. Approximately 8.2% of the shares of the company are short sold.

Integer Stock Performance

Integer stock traded up $2.66 during mid-day trading on Wednesday, reaching $121.22. The company had a trading volume of 390,720 shares, compared to its average volume of 329,356. The company has a 50 day moving average of $129.52 and a 200-day moving average of $131.97. The firm has a market cap of $4.08 billion, a price-to-earnings ratio of 36.08, a PEG ratio of 1.72 and a beta of 1.24. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62. Integer has a 52 week low of $107.11 and a 52 week high of $146.36.

Integer (NYSE:ITGR) last issued its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). The company had revenue of $449.50 million during the quarter, compared to analyst estimates of $446.28 million. Integer had a return on equity of 11.65% and a net margin of 6.92%. On average, sell-side analysts expect that Integer will post 6.01 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Benchmark upped their price objective on shares of Integer from $140.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Wells Fargo & Company reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Integer in a report on Tuesday, December 3rd. Raymond James assumed coverage on Integer in a report on Friday, March 28th. They issued an “outperform” rating and a $145.00 price objective on the stock. KeyCorp boosted their target price on shares of Integer from $144.00 to $154.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Finally, Oppenheimer lowered Integer from an “outperform” rating to a “market perform” rating in a research report on Friday, February 21st. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $148.56.

Institutional Investors Weigh In On Integer

A number of hedge funds and other institutional investors have recently made changes to their positions in ITGR. Mather Group LLC. lifted its stake in Integer by 304.3% in the fourth quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 143 shares during the last quarter. Lee Danner & Bass Inc. bought a new stake in shares of Integer during the fourth quarter worth approximately $27,000. R Squared Ltd acquired a new position in shares of Integer in the fourth quarter valued at about $44,000. Sterling Capital Management LLC raised its holdings in Integer by 472.9% in the 4th quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 279 shares in the last quarter. Finally, Versant Capital Management Inc boosted its position in shares of Integer by 98.4% during the 4th quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider’s stock worth $49,000 after acquiring an additional 183 shares in the last quarter. 99.29% of the stock is currently owned by institutional investors and hedge funds.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.